PolarityTE (PTE) Stock Price
PolarityTE Price
Revenue at PolarityTE has contracted by 23.1% per year over the past 19 years to 814,000.00 USD. Earnings per share have declined at 1.4% per year over the last 4 years. For PolarityTE, the net margin of -962.3% is up versus -2,628.6% a few years ago. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
PolarityTE stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PolarityTE business model & stock analysis
Frequently asked questions about PolarityTE
The business model of PolarityTE Inc is focused on regenerative medicine. The company develops and commercializes innovative tissue regeneration products. PolarityTE aims to transform the lives of patients by providing them with advanced regenerative solutions. Their technology platform is based on a revolutionary approach to regenerate full-thickness, functional tissues and organs. By utilizing a patient's own cells, PolarityTE aims to eliminate the need for conventional grafts, transplants, or artificial materials. The company's commitment to regenerative medicine and their revolutionary tissue regeneration approach sets them apart in the healthcare industry.
PolarityTE Inc is primarily active in the healthcare industry.
The main competitors of PolarityTE Inc in the market include companies such as Organovo Holdings Inc, Acelity Holdings Inc, and Avita Medical Ltd.
PolarityTE Inc, founded in 2014, is a regenerative medicine company based in Salt Lake City, Utah. The company focuses on developing and commercializing innovative tissue products for various therapeutic applications. PolarityTE's proprietary platform, known as the PolarityTE Platform, enables the regeneration of functional tissues perfect for patients in need. With a strong emphasis on research and development, PolarityTE strives to revolutionize healthcare by providing cutting-edge solutions for tissue repair and regeneration. As a leading player in the regenerative medicine sector, PolarityTE Inc has gained recognition for its unique approach and promising advancements in the field.
PolarityTE Inc has achieved several significant milestones. The company successfully developed the PolarityTE platform, a regenerative medicine solution that enables the regeneration of functional tissues. They obtained FDA clearance for their flagship product, SkinTE, which is a minimally manipulated autologous cell therapy for treating skin wounds. Additionally, PolarityTE expanded its product offerings to include bone and muscle regeneration. The company also established partnerships with renowned medical institutions, boosting its credibility and research capabilities. PolarityTE Inc's dedication to innovative regenerative medicine solutions and its achievements in FDA clearances and product expansions have solidified its position in the healthcare industry.
PolarityTE Inc, a professional stock website, primarily presents its presence in multiple countries and regions worldwide. With a global perspective, PolarityTE Inc operates in various markets, including North America, Europe, Asia-Pacific, and other parts of the world. As a multinational company, PolarityTE Inc has established its footprint in major economies to leverage opportunities and foster growth. With a diversified geographical presence, the company aims to serve a wide range of customers and tap into diverse market potentials. PolarityTE Inc's international reach demonstrates its commitment to expanding its operations and establishing a global presence in the stock market.
PolarityTE Inc represents a strong commitment to innovation, integrity, and patient-centricity. The company’s corporate philosophy revolves around transforming the lives of patients through regenerative medicine solutions. PolarityTE Inc aims to revolutionize the healing process by developing cutting-edge technologies that promote self-healing in a regenerative manner. With a focus on cellular therapies and tissue engineering, the company strives to provide efficient and effective treatment options for patients. PolarityTE Inc’s dedication to advancing regenerative medicine demonstrates their dedication to improving healthcare outcomes and enhancing the overall quality of life for individuals in need.
5 analysts currently rate the PolarityTE stock: 4 recommend buying, 1 holding and 0 selling.
The PolarityTE share (PTE) is listed on 1 stock exchanges, including: NASDAQ (PTE).
PolarityTE Inc. is a biopharmaceutical company specializing in the development of regenerative medical products for various applications. The company is headquartered in Salt Lake City, Utah and was founded in 2014. PolarityTE's business model is based on the development and commercialization of products that are based on proprietary technologies for tissue restoration and strengthening. The company utilizes regenerative medicine to stimulate the body's self-healing. PolarityTE has two main divisions: SkinTE and OsteoTE. SkinTE is a regeneration product for the skin used in the healing of burns, skin injuries, and wounds. OsteoTE is a bone regeneration product used in the treatment of bone defects and orthopedic conditions. The processes utilized by PolarityTE to manufacture these products are based on a unique technology called tissue engineering. Cells are extracted from the patient's body and cultivated in a special solution, allowing them to multiply and differentiate into specific tissue types. The cells are then applied to a special carrier and implanted into the patient's body. PolarityTE's products have the potential to change the way physicians treat tissue damage and loss. Instead of relying on synthetic implants and transplants, doctors can now utilize the body's own resources to replace lost tissue. This leads to faster healing, fewer infections, and fewer complications compared to traditional methods. PolarityTE has also partnered with Massachusetts General Hospital (MGH) and Harvard Medical School to explore the use of its technology in the treatment of inguinal hernias. The collaboration will allow PolarityTE to expand its expertise in the field of regenerative medicine and discover new applications for its technology. The company has also entered into agreements with various hospitals and medical facilities to test and validate its products, as well as market its technology. PolarityTE sells its products directly to physicians as well as hospitals and medical facilities to ensure accessibility on a wide scale. Overall, PolarityTE is an innovative company with a promising approach and strong potential to revolutionize regenerative medicine. The company has already made impressive progress in the development of products based on its proprietary tissue restoration and strengthening technologies. As one of the most promising companies in the industry, PolarityTE has the ability to change the lives of patients worldwide by accelerating healing processes and improving outcomes.
The revenue cannot currently be calculated for PolarityTE.
The profit cannot currently be calculated for PolarityTE.
The P/E ratio cannot be calculated for PolarityTE at the moment.
The P/S cannot be calculated for PolarityTE currently.
The Eulerpool Quality Score for PolarityTE is 2/10.
The ISIN of PolarityTE is US7310941080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of PolarityTE is A2DKCN. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of PolarityTE is PTE. The ticker symbol is used to trade PolarityTE shares on the stock exchange.
PolarityTE stock
PolarityTE Peer Group
PolarityTE Ticker
PolarityTE FIGI
All fundamentals and in-depth analysis of PolarityTE
Our stock analysis for PolarityTE stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PolarityTE. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.